Acquisition Details
Eli Lilly and Company has entered into a definitive agreement to acquire Ventyx Biosciences for approximately $1.2 billion in an all-cash transaction. The purchase price of $14.00 per share represents a 62% premium to Ventyx's 30-day volume-weighted average trading price as of January 5, 2026. The transaction is expected to close in the first half of 2026, pending approval by Ventyx stockholders and regulatory authorities.
Ventyx's Clinical Pipeline
Ventyx Biosciences, a clinical-stage biopharmaceutical company, is developing a pipeline of small molecule therapeutics, including NLRP3 inhibitors. These are designed to treat inflammation across various disease states with high unmet needs, such as cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's clinical-stage programs aim to offer improved efficacy and safety compared to existing treatments by targeting key immune pathways.
Strategic Implications
The acquisition builds on Lilly's established capabilities in inflammatory-mediated diseases, enhancing its ability to deliver advances for patients with challenging conditions in cardiometabolic health, neurodegeneration, and autoimmunity. The boards of directors of both companies have approved the transaction, and entities affiliated with New Science Ventures, along with all directors and officers of Ventyx, have signed voting and support agreements to approve the deal.
